Edition:
United Kingdom

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

136.12USD
9:00pm BST
Change (% chg)

$-2.97 (-2.14%)
Prev Close
$139.09
Open
$140.01
Day's High
$140.01
Day's Low
$134.70
Volume
222,347
Avg. Vol
192,812
52-wk High
$199.35
52-wk Low
$87.64

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency Panel Recommends Conditional Approval Of Bluebird Bio's Zynteglo
Friday, 29 Mar 2019 

March 29 (Reuters) - European Medicines Agency::EU MEDICINES AGENCY PANEL RECOMMENDS APPROVAL OF BLUEBIRD BIO’S GENE THERAPY ZYNTEGLO FOR TREATMENT OF A TYPE OF BLOOD DISORDER WITH CONDITIONS.  Full Article

Bluebird Bio Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Operational Progress
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $19.2 MILLION VERSUS $4.2 MILLION.Q4 REVENUE ESTIMATE $8.1 MILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $2.72.Q4 EARNINGS PER SHARE VIEW $-2.86 -- REFINITIV IBES DATA.  Full Article

Bluebird Bio Appoints Chip Baird From Amicus Therapeutics As CFO
Monday, 11 Feb 2019 

Feb 11 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO APPOINTS CHIP BAIRD AS CHIEF FINANCIAL OFFICER.BLUEBIRD BIO INC - JEFF WALSH TO ASSUME ROLE OF CHIEF STRATEGY OFFICER.BLUEBIRD BIO INC - JASON COLE TO ASSUME ROLE OF CHIEF OPERATING AND LEGAL OFFICER.BLUEBIRD BIO INC - BAIRD JOINS BLUEBIRD FROM AMICUS THERAPEUTICS.  Full Article

Bluebird Bio Q3 Revenue $11.5 Million
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q3 REVENUE $11.5 MILLION VERSUS $7.7 MILLION.Q3 REVENUE VIEW $7.5 MILLION -- THOMSON REUTERS I/B/E/S.ENDED QUARTER WITH $2.0 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.ANTICIPATES THAT ITS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2022.QTRLY LOSS PER SHARE $2.73.COMPANY PLANS TO PURSUE ACCELERATED DEVELOPMENT PATHWAY FOR LENTIGLOBIN(TM) IN SICKLE CELL DISEASE (SCD).Q3 EARNINGS PER SHARE VIEW $-2.84 -- THOMSON REUTERS I/B/E/S.  Full Article

Bluebird Bio Reports Q4 Loss Per Share $2.52‍​
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $4.2 MILLION VERSUS $1.6 MILLION.‍ENDED YEAR WITH $1.6 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.QTRLY LOSS PER SHARE $2.52‍​.  Full Article

Bluebird Bio Expects Three Regulatory Filings By End 2019
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019.BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018.BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019.  Full Article

Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICED UNDERWRITTEN PUBLIC OFFERING OF 3.2 MILLION SHARES OF ITS COMMON STOCK AT $185 PER SHARE​.  Full Article

Bluebird Bio Announces Proposed Public Offering Of Common Stock
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BLUEBIRD BIO INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $600 MILLION OF ITS COMMON STOCK.  Full Article

bluebird bio And TC BioPharm Announce Strategic Collaboration
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY.BLUEBIRD BIO INC - FINANCIAL TERMS OF AGREEMENT INCLUDE A $16 MILLION UPFRONT PAYMENT.BLUEBIRD BIO - FINANCIAL TERMS OF AGREEMENT ALSO INCLUDE POTENTIAL RESEARCH AND DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS.BLUEBIRD BIO - AS PART OF DEAL, TC BIOPHARM ALSO ELIGIBLE TO GET UNDISCLOSED TIERED ROYALTIES ON PRODUCT SALES.BLUEBIRD BIO INC - CO, TC BIOPHARM WILL WORK TOGETHER TO ADVANCE TC BIOPHARM'S LEAD CAR-ENGINEERED GAMMA DELTA T CELL PROGRAM INTO CLINICAL TRIALS.  Full Article

Bluebird Bio Acquires Manufacturing Facility In North Carolina
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS.  Full Article

UPDATE 1-EMA panel recommends approval of Bluebird Bio's first gene therapy

March 29 A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.